<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02803619</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-595</org_study_id>
    <nct_id>NCT02803619</nct_id>
  </id_info>
  <brief_title>A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <brief_summary>
    <textblock>
      Leptomeningeal metastasis (LM) is one of the disastrous events when managing advanced
      Non-small cell lung cancer (NSCLC) due to a grave prognosis. Although intrathecal (IT)
      chemotherapy and brain and/or spinal axis irradiation show some effects for LM in advanced
      NSCLC, the prognosis is still poor with median survival less than 12-14 weeks. Epidermal
      growth factor (EGFR) tyrosine kinase inhibitors (TKIs) showed to be effective for LM in
      selected NSCLC patients in some retrospective research. Our single-center prospective
      research indicated that the incidence of EGFR sensitive mutations (EGFRm+) in NSCLC-LM
      patients was high and EGFR-TKIs showed a survival benefit for LM in EGFRm+ NSCLC patients. A
      multi-center prospective observational biomarker study will be started in 11 lung cancer
      center based on our single-center prospective research result. The aims of the study are to
      find predictive biomarkers for LM in advanced NSCLC, to establish EGFR-TKIs based
      comprehensive treatment for appropriate EGFRm+ LM cases, and to establish effective clinical
      assessment criteria for NSCLC-LM EGFR-TKIs treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival after the diagnosis of leptomeningeal metastasis in NSCLC patients</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Leptomeningeal Metastasis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Leptomeningeal metastasis (LM) in patients with non-small cell lung cancer (NSCLC)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The cytological identification of malignant cells within cerebrospinal fluid (CSF).

          2. Non-small cell lung cancer patients.

          3. Tumor specimens or cytology specimens can be used for the EGFR gene mutation
             detection.

          4. The entails examining cerebrospinal fluid could be obtained by lumbar puncture.

          5. Expected survival time is greater than 1 month.

        Exclusion Criteria:

        Patients with radiologic evidence of LM not confirmed by positive CSF cytology.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mengzhao Wang, MD</last_name>
    <phone>010-69155039</phone>
    <phone_ext>+86</phone_ext>
    <email>mengzhaowang@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Respiratory Medicine, Peking Union Medical College Hospita</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mengzhao Wang, MD</last_name>
      <phone>010-69155039</phone>
      <phone_ext>+86</phone_ext>
      <email>mengzhaowang@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Yan Xu, MD</last_name>
      <phone>18500296828</phone>
      <phone_ext>+86</phone_ext>
      <email>maraxu@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yan Xu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei Zhong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>June 16, 2016</last_update_submitted>
  <last_update_submitted_qc>June 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Wang mengzhao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>leptomeningeal metastasis</keyword>
  <keyword>EGFR sensitive mutations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

